PIE, or a preapproval information exchange, is aimed at streamlining payer and health plan involvement so that it happens at the same time a drug developer submits an application to the FDA, instead of after a drug is approved, with the intent of speeding patient access to therapies.
Christina Polomoff, PharmD, BCACP, BCGP, discusses the differences between manufacturer coupons and cash cards and how they financially affect health plans and pharmacies.
Jonathan Silverberg, MD, PhD, MPH, is an author of the poster, “Efficacy of Ruxolitinib Cream Among Patients With Atopic Dermatitis Based on Previous Medication History: Pooled Results From Two Phase 3 Studies,” which will be presented at this year’s American Academy of Dermatology Virtual Meeting Experience (AAD VMX).
On day 2 of this year’s Community Oncology Conference, a panel of government and health policy experts gathered to discuss the hot-button issue of political influence on cancer policy and the damage community oncology has suffered this past year.
There are many sources, and definitions, of where the value in cancer care lies. In this panel discussion, a cancer survivor and patient advocate, an oncologist, and a benefits professional provided their perspectives on what value in cancer care means to them.
Lalan Wilfong, MD, executive vice president, Value Based Care & Quality Programs, Texas Oncology, and cochair, Payment Reform, Community Oncology Alliance, speaks on the evolution of remote monitoring in cancer care and how value-based oncology may look in the near future.
Edward Licitra, MD, PhD, medical oncologist, Astera Health Partners, discusses his thoughts on what value-based cancer care entails and how physicians can best align their goals with those of the patient and health plan.
A popular misconception of palliative care is that it only has importance toward making patients comfortable at the end of their lives, noted a palliative care physician on the first day of the 2021 Community Oncology Conference, presented by the Community Oncology Alliance.
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, discusses cost-saving implications of biosimilars in oncology, as well as several barriers that continue to impede their use.
Ted Okon, MBA, executive director of the Community Oncology Alliance, discusses what influence the new administration may have on payment reform in oncology and issues regarding the 340B drug pricing program.
Day 1 of this year’s virtual Community Oncology Conference opened with a panel discussion that touched on all things related to the COVID-19 pandemic, with leaders presenting a unified front.
Jeff Patton, MD, CEO, OneOncology, and chairman of the board, Tennessee Oncology, discusses what influence COVID-19 will have on discussions at the Community Oncology Conference 2021, as well as takeaways he hopes audience members and participants gain from the conference.
Lalan Wilfong, MD, executive vice president, Value Based Care & Quality Programs, Texas Oncology, and co-chair, Payment Reform, Community Oncology Alliance, discusses implications of quality metrics in cancer care and what perspectives on the topic he is looking forward to hearing at the 2021 Community Oncology Conference.
Research presented at the 2021 Cholangiocarcinoma Foundation Annual Meeting focused on precision medicine and therapeutic targets.
Dinesh Kapur, MD, chair, OneCouncil, and managing partner, Eastern Connecticut Hematology and Oncology (ECHO), speaks on efforts made by by community oncology practices to improve minority representation in oncology clinical trials and implications of the COVID-19 pandemic ahead of the 2021 Community Oncology Conference.
At the 2021 Cholangiocarcinoma Foundation Annual Conference, experts discussed clinical trials in cholangiocarcinoma and the ways in which clinical trials overall can be made more available to patients.
Michael I. D'Angelica, MD, FACS, of Memorial Sloan Kettering Cancer Center, gives insight on genomic testing and its growing role in cholangiocarcinoma.
Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, discusses some of the key aspects of successful trials.
Last year, pemigatinib, the first targeted therapy in cholangiocarcinoma was approved for previously treated patients with FGFR2 fusions or rearrangements.
At the 2021 Cholangiocarcinoma Foundation Annual Conference, experts discussed guidelines and real-world data for the management of urgent symptoms in patients with cholangiocarcinoma who have biliary stents or drains.
Funda Meric-Bernstam, MD, co-chair of the 2021 Cholangiocarcinoma Foundation Annual Conference, gives her insight on immunotherapies in cholangiocarcinoma.
Michael I. D'Angelica, MD, FACS, of Memorial Sloan Kettering Cancer Center, discusses multidisciplinary care and why it is so important in hepatobiliary cancers.
Kathy Oubre, MS, chief operating officer, Pontchartrain Cancer Center, explores US adoption of biosimilars ahead of her panel discussion at the 2021 Community Oncology Conference, as well as what sessions she’s looking forward to attending.
On the first day of the Cholangiocarcinoma Foundation Annual Meeting, Elli Brimble, MS, MSc, Ciitizen’s head of Clinical Operations, offered insights from an ongoing study based on data provided by patients.
Discussions at the start of the 2021 Annual Cholangiocarcinoma Foundation Conference centered on challenges and advances made during the COVID-19 pandemic, and the potential of liver transplantation in cholangiocarcinoma.
Funda Meric-Bernstam, MD, co-chair of the 2021 Cholangiocarcinoma Foundation Annual Conference, gives her input on the importance of hearing from patients and advocates as well as physicians in discussions around cholangiocarcinoma treatment.
Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, stresses the importance of approaching difficult hepatobiliary cancer settings with a multifaceted care team.
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, highlights his questions for the keynote speakers of the 2021 Community Oncology Conference, and takeaways he hopes audience members gain from the sessions.
Ted Okon, MBA, executive director, Community Oncology Alliance (COA), speaks on the most significant challenges members encountered in the past year managing the COVID-19 pandemic ahead of the 2021 Community Oncology Conference.
Jeff Patton, MD, CEO, OneOncology, chairman of the board, Tennessee Oncology, discusses what audience members should expect from the Community Oncology Conference 2021 and sessions he is looking forward to.
